Conference Dates

June 12 – 17, 2022


Vaccines for known and emerging diseases as well as new therapeutic applications of viruses will require multiple doses and high virus input per dose or treatment. Therefore, there is a clear need for innovation in vaccine manufacturing. Yet, process optimization and intensification are cost- and labor-intensive challenges and thus not always considered as economically reasonable. To tackle this problem and compete against outdated cost calculations, this work aims to transfer knowledge and techniques that were acquired within a decade of protein production process development into the field of viral vaccine manufacturing. This comprises the development of monoclonal suspension MDCK cell lines using an automated single-cell cloning strategy in chemically defined medium. Subsequently, a scale-down into the fully automated single-use Ambr®15 microbioreactor system (Sartorius, Germany) was established for influenza A virus (IAV) production. This may help to accelerate process development and optimization by parallelized screening of multiple parameters in a high-throughput manner.

Please click Download on the upper right corner to see the full abstract.